Muscle Spasticity Clinical Trial Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working in the Domain | DelveInsight

DelveInsight's "Muscle Spasticity Pipeline Insight 2025" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Muscle Spasticity pipeline landscape. It covers the Muscle Spasticity pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Muscle Spasticity pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Muscle Spasticity Pipeline? Click here to explore the therapies and trials making headlines @ https://www.delveinsight.com/sample-request/muscle-spasticity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Muscle Spasticity Pipeline Report
• On December 05, 2025- Celgene announced a Phase 2, Randomized, Double-Blind, Four-Arm, Placebo-Controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of Three Doses of Orally Administered BMS-986368, a FAAH/MAGL Inhibitor, for the Treatment of Spasticity in Participants With Multiple Sclerosis (BALANCE-MSS-1).
• On December 04, 2025- Merz Pharmaceuticals GmbH conducted a study is to determine whether a single treatment with administration of 400 Units NT 201 (botulinum toxin) is superior to placebo (no medicine) for the treatment of lower limb spasticity caused by stroke or traumatic brain injury (Main Period). Participants will be assigned to the treatment groups by chance and neither the participants nor the research staff who interact with them will know the allocation.
• On December 04, 2025- Ipsen initiated a Phase I/II study is to assess the safety and efficacy of increasing doses of IPN10200 with the aim to evaluate the Pharmacodynamics (PD) profile of IPN10200 and to establish the total IPN10200 doses(s) that offer the best efficacy/safety profile when used for the treatment of Adult upper limb (AUL) spasticity.
• DelveInsight's Muscle Spasticity Pipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Muscle Spasticity treatment.
• The leading Muscle Spasticity Companies, such as Saol Therapeutics, Daewoong Pharmaceutical, AbbVie, Supernus Pharmaceuticals, Revance Therapeutics, Ipsen, Abide Therapeutics, Motor Pharma, BetterLife Pharma RVL Pharmaceuticals and others.
• Promising Muscle Spasticity Therapies such as CORETOX®, BOTOX®, XP19986 SR1, 10 mg BID, Meditoxin, Tizanidine (sublingual or oral), SPARC0921, IPN10200, Arbaclofen and others.

Want to know which companies are leading innovation in Muscle Spasticity? Dive into the full pipeline insights @ https://www.delveinsight.com/sample-request/muscle-spasticity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

The Muscle Spasticity Pipeline Report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Muscle Spasticity Pipeline Report also highlights the unmet needs with respect to the Muscle Spasticity.

Muscle Spasticity Overview
Muscle spasticity is a condition in which muscles become stiff, tight, and difficult to control due to continuous, involuntary contractions. It occurs when the nerve signals that regulate muscle movement are disrupted, typically because of damage to the brain or spinal cord. As a result, the affected muscles resist movement, making activities like walking, stretching, or maintaining posture challenging. Spasticity is commonly seen in neurological disorders such as cerebral palsy, multiple sclerosis, spinal cord injuries, stroke, and traumatic brain injury.

Muscle Spasticity Emerging Drugs Profile
• Arbaclofen ER: Janssen Pharmaceutical
Arbaclofen ER is an extended release formulation of arbaclofen, the R isomer of baclofen that leverages our proprietary Osmodex® drug delivery system and is being studied for the treatment of spasticity resulting from multiple sclerosis.

• Lu AG06466: Abide Therapeutics
Lu AG06466 (formerly ABX 1431) is an oral, small molecule, being developed by Abide Therapeutics (now Lundbeck A/S), for the treatment of neuropathic pain, pain in irritable bowel syndrome, multiple sclerosis associated spasticity [muscle spasticity in the development table], fibromyalgia and epilepsy.

If you're tracking ongoing Muscle Spasticity Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ https://www.delveinsight.com/sample-request/muscle-spasticity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

The Muscle Spasticity Pipeline report provides insights into:-
• The report provides detailed insights about companies that are developing therapies for the treatment of Muscle Spasticity with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Muscle Spasticity Treatment.
• Muscle Spasticity Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Muscle Spasticity Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Muscle Spasticity market.

Muscle Spasticity Companies
Saol Therapeutics, Daewoong Pharmaceutical, AbbVie, Supernus Pharmaceuticals, Revance Therapeutics, Ipsen, Abide Therapeutics, Motor Pharma, BetterLife Pharma RVL Pharmaceuticals and others.

Muscle Spasticity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous

Muscle Spasticity Products have been categorized under various Molecule types such as
• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

From emerging drug candidates to competitive intelligence, the Muscle Spasticity Pipeline Report covers it all - check it out now @ https://www.delveinsight.com/sample-request/muscle-spasticity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Muscle Spasticity Pipeline Report
• Coverage- Global
• Muscle Spasticity Companies- Saol Therapeutics, Daewoong Pharmaceutical, AbbVie, Supernus Pharmaceuticals, Revance Therapeutics, Ipsen, Abide Therapeutics, Motor Pharma, BetterLife Pharma RVL Pharmaceuticals and others.
• Muscle Spasticity Therapies- CORETOX®, BOTOX®, XP19986 SR1, 10 mg BID, Meditoxin, Tizanidine (sublingual or oral), SPARC0921, IPN10200, Arbaclofen and others.
• Muscle Spasticity Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Muscle Spasticity Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research - discover what's next for the Muscle Spasticity Treatment landscape in this detailed analysis @ https://www.delveinsight.com/sample-request/muscle-spasticity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Introduction
2. Executive Summary
3. Muscle Spasticity: Overview
4. Pipeline Therapeutics
5. Therapeutics Assessment
6. Muscle Spasticity- DelveInsight's Analytical Perspective
7. Late Stage Products (Preregistration)
8. Arbaclofen ER: RVL Pharmaceuticals
9. Mid Stage Products (Phase II)
10. SIL1002: Saol Therapeutics
11. Drug profiles in the detailed report.....
12. Early Stage Products (Phase I)
13. Lu AG06466: Abide Therapeutics
14. Drug profiles in the detailed report.....
15. Preclinical Stage Products
16. Inactive Products
17. Muscle Spasticity Key Companies
18. Muscle Spasticity Key Products
19. Muscle Spasticity- Unmet Needs
20. Muscle Spasticity- Market Drivers and Barriers
21. Muscle Spasticity- Future Perspectives and Conclusion
22. Muscle Spasticity Analyst Views
23. Muscle Spasticity Key Companies
24. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.